Celea Therapeutics Secures $180 Million to Launch SURPASS-IPF Phase 3 Trial Against Standard of Care

A $180 million financing round positions Celea Therapeutics to initiate what would be the first head-to-head Phase 3 trial in idiopathic pulmonary fibrosis, with clinical supply chains and contract manufacturers likely to feel the earliest operational pressure as enrollment ramps.

The capital is earmarked to fund the global SURPASS-IPF Phase 3 trial, targeting a launch in early Q3 2026. The study is structured as a direct comparison against existing standard-of-care therapies, a design that raises the bar for comparator sourcing, blinding logistics, and investigational product release timelines across participating sites.

For CMOs and clinical supply partners already operating under 21 CFR Part 211 and ICH Q10 quality management frameworks, a global Phase 3 in a high-scrutiny indication like IPF introduces layered complexity: comparator procurement, cold-chain integrity across international depots, and batch release cadences aligned to enrollment velocity. QA directors at contract sites should anticipate heightened documentation requirements given the head-to-head design, which invites closer regulatory scrutiny of manufacturing consistency across both arms.

The fibrosis space has seen incremental clinical movement over the past decade, but a powered head-to-head Phase 3 represents a structural shift in how regulators and payers will evaluate efficacy claims going forward. Regulatory affairs leads tracking FDA and EMA precedent in rare respiratory indications will note that comparative trial data, when available, increasingly shapes labeling negotiations and post-approval commitments.

Celea has not disclosed the trial's geographic footprint or the number of investigational sites, details that will determine the scale of GMP-compliant clinical material production and distribution infrastructure required before first patient in.

The SURPASS-IPF enrollment timeline, expected to clarify in Q3 2026, will serve as the first measurable checkpoint for supply chain partners assessing capacity commitments against the program.

Source: Media4Growth via Indian Pharma Post, 6 July 2026.